About Genesys Capital
Genesys Capital is a venture capital firm founded in 2000. It is primarily based out of Toronto, Canada. As of Jan 2026, Genesys Capital is an active investor, having invested in 32 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in Canada based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of Enspire DBS Therapy Overall, Genesys Capital portfolio has seen 2 IPOs and 9 acquisitions including key companies like Invitae, Profound Medical and Fusion Pharmaceuticals. A lot of funds co-invest with Genesys Capital, with names like BDC sharing a substantial percentage of its portfolio. Genesys Capital has team of 6 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 2 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Genesys Capital's List of Top Investments
Genesys Capital has a portfolio of 32 companies. Their most notable investments are in Profound Medical and Inversago Pharma.Their portfolio spans across Canada, United States and Israel. They have invested in Life Sciences, High Tech, HealthTech and 5 other sectors, across stages such as Series A, Seed and 2 more. Here is the list of top investments by Genesys Capital:1. Invitae
Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.
Key facts about Invitae
- Founded Year: 2010
- Location: San Francisco (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $190M
- Employee Count: 675 as on Sep 30, 2026
- Investors: Scheuermann Investment, Perceptive Advisors and 22 Others
- Latest Funding Round: Post IPO, Apr 05, 2021, $*****
- Highlight: Public
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
Key facts about Profound Medical
- Founded Year: 2008
- Location: Toronto (Canada)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $37.7M
- Employee Count: 187 as on Sep 30, 2026
- Investors: Stifel, FedDev Ontario and 11 Others
- Latest Funding Round: Post IPO, Dec 19, 2025, $*****
- Highlight: Public
_1568087563364.png?format=webp&height=120&width=120){kind=logo}
Veralox Therapeutics is developing small molecule therapeutics for targeting pathways related to the pathologies of thrombosis and type 1 diabetes. The company is developing small molecules to target arachidonic acid (AA) pathway protein 12-lipoxygenase required for the production of 12-HETE involved in the development of multiple diseases.
Key facts about Veralox Therapeutics
- Founded Year: 2017
- Location: Frederick (United States)
- Stage: Series B
- Total Funding till date: $47.5M
- Employee Count: 6 as on Dec 31, 2021
- Investors: Sanofi Ventures, TEDCO and 13 Others
- Latest Funding Round: Series B, Jun 21, 2023, $*****
- Highlight: Editors' Pick
Flosonics Medical is a developer of non-invasive sensors for the management of critically ill patients, performing continuous monitoring of arterial flow with automatic artery detection. The company develops products for fluid responsiveness detection in the ICU, E.D, and operating room. The company's smart-bandage product, FloPatch, is designed to address the clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit. The patch is disposable and is enabled with ultrasound technology.
Key facts about Flosonics Medical
- Founded Year: 2015
- Location: Greater Sudbury (Canada)
- Stage: Series C
- Total Funding till date: $39M
- Employee Count: 75 as on Sep 30, 2026
- Investors: New Leaf Venture Partners, Graphite Ventures and 15 Others
- Latest Funding Round: Venture Debt, Mar 03, 2025, $*****
- Highlight: Editors' Pick
5. EBT Medical
EBT Medical is developing non-invasive neurostimulation therapies and disease state support systems for pelvic floor disorders, starting with overactive bladder. It delivers long-lasting pharmaceutical or invasive therapy-equivalent efficacy without the side-effects, invasiveness, or costs that are typically associated with those therapies.
Key facts about EBT Medical
- Founded Year: 2014
- Location: Toronto (Canada)
- Stage: Series A
- Total Funding till date: $10M
- Employee Count: 11 as on Aug 31, 2026
- Investors: Canadian Institutes of Health Research, Genesys Capital and 8 Others
- Latest Funding Round: Series A, Nov 19, 2019, $*****
Genesys Capital's Year-on-Year Investment Trends
Genesys Capital has invested in 32 companies over the last 23 years, with an average of 1 new investment annually in the last 10 years. As of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Enspire DBS Therapy and most recent follow-on round was in Flosonics Medical.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 0 | 0 | 0 |
2024 | 1 | 1 | 2 |
2023 | 1 | 1 | 2 |
2022 | 1 | 1 | 2 |
2021 | 2 | 1 | 3 |
2020 | 1 | 0 | 1 |
2019 | 1 | 1 | 2 |
2018 | 3 | 0 | 3 |
2017 | 1 | 0 | 1 |
Genesys Capital's Investments by Stage
Genesys Capital has made 13 investments in Series A stage with an average round size of $12.3M, 4 investments in Seed stage with an average round size of $8M, 3 investments in Series B stage with an average round size of $17.1M and 1 investment in Series E stage with an average round size of $40M.Stage of entry | No. of Investments |
|---|---|
Series A | 13 |
Seed | 4 |
Series B | 3 |
Series E | 1 |
Note: We have considered here, only first round of investments
Genesys Capital's Investments by Sector
Genesys Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Consumer and Enterprise Applications. Notably, it has invested in 28 Tech companies, 26 Enterprise (B2B) companies, 7 Software companies and at least 6 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 20 |
High Tech | 6 |
HealthTech | 3 |
Consumer | 2 |
Enterprise Applications | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Genesys Capital's Investments by Geography
Genesys Capital has made most investments in Canada (13), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
Canada | 13 |
United States | 7 |
Israel | 1 |
Note: We have considered here, only first round of investments
Genesys Capital's recent investments
Genesys Capital has made 1 investments in 2026 so far - Enspire DBS Therapy.Here are the most recent investments by Genesys Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 13, 2026 | United States | Series B | 7472 | ||
Sep 04, 2024 | Canada | Series B | 4140 | ||
May 03, 2024 | Canada | Series C | 5326 | ||
Jul 27, 2023 | Canada | Seed | 3691 | - | |
Jun 21, 2023 | United States | Series B | 8835 | [+4] |
IPOs and Publicly Listed companies in Genesys Capital's Portfolio
2 of Genesys Capital's portfolio companies have become public. Profound Medical got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2017 at marketcap of $2.53M and Invitae got listed on the New York Stock Exchange (NYSE) at marketcap of $493M.Here are Genesys Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 17, 2017 | May 30, 2011 | Series A | 2997 | |
Feb 13, 2015 | Dec 10, 2013 | Series E | 6773 |
Acquired companies in Genesys Capital's Portfolio
9 companies from Genesys Capital's portfolio have been acquired. The most recent acquisition was Fusion Pharmaceuticals in Mar 2024 by AstraZeneca for $*****.Here are Genesys Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 19, 2024 | Feb 23, 2017 | Series A | 6603 | |
Jun 24, 2022 | Jan 29, 2020 | Series B | 4397 | |
Jan 07, 2020 | - | - | 6615 | |
Jul 21, 2017 | 2003 | Series A | 5884 | |
Jul 26, 2015 | May 11, 2011 | Series A | 5753 |
Team profile of Genesys Capital
Genesys Capital has a team of 6 members including 3 Partners, 1 Venture Partner and 1 Principal located in Canada, France and 1 more location. Genesys Capital's team sits on the board of 1 company.Here is a list of all team members in Genesys Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Toronto | |||
Partner | Toronto | - | ||
Partner | Paris | - | ||
Venture Partner | United States | - | ||
Principal | Toronto | - |
Co-investors of Genesys Capital
Over the past 23 years, 125 investors have co-invested in Genesys Capital's portfolio companies. This includes only funds.
- Invested before Genesys Capital: Sanofi Ventures, T1D Fund and 22 others have invested in rounds before Genesys Capital. There is 1 company where Sanofi Ventures has invested before Genesys Capital and 1 company where T1D Fund has invested before Genesys Capital.
- Top Co-investors of Genesys Capital: 44 investors entered a company along with Genesys Capital. These include investors like BDC (2 companies).
- Invested after Genesys Capital: A total of 57 investors have invested in Genesys Capital's portfolio after their investments. Top Investors include Orbimed (3 companies), Perceptive Advisors (2 companies) and Rock Springs Capital (2 companies).
Recent News related to Genesys Capital
•
Genesys Capital Announces Second Close of Genesys University Seed Fund, Welcoming Sunnybrook and UHN as Hospital PartnersBusiness Wire•Oct 13, 2026•Genesys Capital, University Health Network, Sunnybrook
•
Enspire DBS Therapy Raises $10.3M in Series B1 FundingFinSMEs•Jan 13, 2026•Enspire DBS Therapy, Genesys Capital, JobsOhio Ventures, Cleveland Clinic
•
Feldan Therapeutics Accelerates Growth With Strategic Investment From Linearis VenturesCNW•Feb 18, 2025•Fonds de solidarite FTQ, Invest Quebec, Genesys Capital, Linearis and 2 others
•
•
Flosonics Procures $20 Million in Series C FundingMedical Product Outsourcing•May 03, 2024•Arboretum Ventures, Genesys Capital, iGan Partners, Flosonics Medical
•
Flosonics Medical Secures $20 Million USD in Series C Funding Led by New Leaf Venture Partners to Accelerate GrowthBusiness Wire•Mar 19, 2024•Flosonics Medical, New Leaf Venture Partners, Arboretum Ventures, Genesys Capital and 1 other
•
Inversago Pharma completes CAD $95 million Series C financing roundBusiness Wire•Oct 17, 2022•Inversago Pharma, New Enterprise Associates, Forbion, Amgen and 5 others
•
Genesys Capital appoints Dr. Maxime Ranger as Venture PartnerBusiness Wire•Jan 13, 2022•Genesys Capital, Giiant Pharma
•
Giiant Pharma Inc Announced the Closing of US$11m in Seed Financing to Develop Its Precision Delivery Technology Platform in GastroenterologyBusiness Wire•May 21, 2021•Giiant Pharma, Amplitude, Genesys Capital, Fonds de solidarite FTQ and 4 others
•
Flosonics Medical Closes $14 Million Financing RoundMedical Product Outsourcing•Feb 12, 2021•Flosonics Medical, Arboretum Ventures, iGan Partners, Genesys Capital
